Medical - Distribution
Compare Stocks
5 / 10Stock Comparison
GRDN vs MCK vs CAH vs CVS vs UNH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
Medical - Distribution
Medical - Healthcare Plans
Medical - Healthcare Plans
GRDN vs MCK vs CAH vs CVS vs UNH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Distribution | Medical - Distribution | Medical - Distribution | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $2.30B | $92.15B | $43.59B | $111.40B | $335.60B |
| Revenue (TTM) | $1.46B | $403.43B | $250.55B | $407.90B | $449.71B |
| Net Income (TTM) | $53M | $4.76B | $1.56B | $2.93B | $12.04B |
| Gross Margin | 20.2% | 3.6% | 3.7% | 13.9% | 18.8% |
| Operating Margin | 6.4% | 1.5% | 0.9% | 1.5% | 4.2% |
| Forward P/E | 28.7x | 16.7x | 17.1x | 12.4x | 20.7x |
| Total Debt | $37M | $7.39B | $9.35B | $93.59B | $78.39B |
| Cash & Equiv. | $66M | $5.69B | $3.87B | $8.51B | $24.36B |
GRDN vs MCK vs CAH vs CVS vs UNH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Guardian Pharmacy S… (GRDN) | 100 | 214.8 | +114.8% |
| McKesson Corporation (MCK) | 100 | 149.0 | +49.0% |
| Cardinal Health, In… (CAH) | 100 | 166.2 | +66.2% |
| CVS Health Corporat… (CVS) | 100 | 144.0 | +44.0% |
| UnitedHealth Group … (UNH) | 100 | 65.0 | -35.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GRDN vs MCK vs CAH vs CVS vs UNH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GRDN carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 17.9%, EPS growth 144.1%, 3Y rev CAGR 16.8%
- 17.9% revenue growth vs CAH's -1.9%
- 3.6% margin vs CAH's 0.6%
- +40.5% vs UNH's -3.2%
MCK is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 348.1% 10Y total return vs CAH's 160.8%
- PEG 0.43 vs GRDN's 1.53
CAH ranks third and is worth considering specifically for income & stability and sleep-well-at-night.
- Dividend streak 20 yrs, beta 0.03, yield 1.1%
- Lower volatility, beta 0.03, current ratio 0.94x
- Beta 0.03, yield 1.1%, current ratio 0.94x
- Beta 0.03 vs GRDN's 1.04
CVS is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (12.4x vs 20.7x)
- 3.1% yield, vs UNH's 2.4%, (1 stock pays no dividend)
Among these 5 stocks, UNH doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.9% revenue growth vs CAH's -1.9% | |
| Value | Lower P/E (12.4x vs 20.7x) | |
| Quality / Margins | 3.6% margin vs CAH's 0.6% | |
| Stability / Safety | Beta 0.03 vs GRDN's 1.04 | |
| Dividends | 3.1% yield, vs UNH's 2.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +40.5% vs UNH's -3.2% | |
| Efficiency (ROA) | 13.4% ROA vs CVS's 1.1%, ROIC 35.8% vs 5.0% |
GRDN vs MCK vs CAH vs CVS vs UNH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GRDN vs MCK vs CAH vs CVS vs UNH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GRDN leads in 2 of 6 categories
CVS leads 1 • MCK leads 0 • CAH leads 0 • UNH leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GRDN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 308.9x GRDN's $1.5B. Profitability is closely matched — net margins range from 3.6% (GRDN) to 0.6% (CAH). On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $403.4B | $250.5B | $407.9B | $449.7B |
| EBITDAEarnings before interest/tax | $112M | $6.8B | $3.2B | $10.5B | $23.2B |
| Net IncomeAfter-tax profit | $53M | $4.8B | $1.6B | $2.9B | $12.0B |
| Free Cash FlowCash after capex | $70M | $6.0B | $4.4B | $7.4B | $19.7B |
| Gross MarginGross profit ÷ Revenue | +20.2% | +3.6% | +3.7% | +13.9% | +18.8% |
| Operating MarginEBIT ÷ Revenue | +6.4% | +1.5% | +0.9% | +1.5% | +4.2% |
| Net MarginNet income ÷ Revenue | +3.6% | +1.2% | +0.6% | +0.7% | +2.7% |
| FCF MarginFCF ÷ Revenue | +4.8% | +1.5% | +1.8% | +1.8% | +4.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +6.0% | +11.0% | +6.2% | +2.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.0% | +37.0% | -19.5% | +63.1% | +0.7% |
Valuation Metrics
CVS leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 27.9x trailing earnings, UNH trades at a 56% valuation discount to CVS's 62.8x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs GRDN's 2.48x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.3B | $92.1B | $43.6B | $111.4B | $335.6B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $93.8B | $49.1B | $196.5B | $389.6B |
| Trailing P/EPrice ÷ TTM EPS | 46.51x | 29.25x | 28.72x | 62.81x | 27.95x |
| Forward P/EPrice ÷ next-FY EPS est. | 28.68x | 16.66x | 17.09x | 12.39x | 20.71x |
| PEG RatioP/E ÷ EPS growth rate | 2.48x | 0.75x | — | — | — |
| EV / EBITDAEnterprise value multiple | 20.40x | 18.74x | 16.01x | 13.11x | 16.70x |
| Price / SalesMarket cap ÷ Revenue | 1.59x | 0.26x | 0.20x | 0.28x | 0.75x |
| Price / BookPrice ÷ Book value/share | 10.54x | — | — | 1.47x | 3.31x |
| Price / FCFMarket cap ÷ FCF | 28.47x | 17.63x | 23.56x | 14.27x | 20.88x |
Profitability & Efficiency
GRDN leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $4 for CVS. GRDN carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), GRDN scores 6/9 vs CVS's 5/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +25.4% | +3.0% | — | +3.9% | +11.5% |
| ROA (TTM)Return on assets | +13.4% | +5.7% | +2.8% | +1.1% | +3.9% |
| ROICReturn on invested capital | +35.8% | +5.4% | +33.8% | +5.0% | +9.2% |
| ROCEReturn on capital employed | +41.5% | +30.5% | +19.2% | +6.1% | +9.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.17x | — | — | 1.24x | 0.77x |
| Net DebtTotal debt minus cash | -$28M | $1.7B | $5.5B | $85.1B | $54.0B |
| Cash & Equiv.Liquid assets | $66M | $5.7B | $3.9B | $8.5B | $24.4B |
| Total DebtShort + long-term debt | $37M | $7.4B | $9.3B | $93.6B | $78.4B |
| Interest CoverageEBIT ÷ Interest expense | 129.16x | 33.79x | 6.38x | 2.11x | 4.71x |
Total Returns (Dividends Reinvested)
Evenly matched — GRDN and MCK and CAH each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $9,743 for UNH. Over the past 12 months, GRDN leads with a +40.5% total return vs UNH's -3.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.9% | -8.5% | -9.5% | +10.6% | +10.6% |
| 1-Year ReturnPast 12 months | +40.5% | +4.6% | +22.0% | +34.7% | -3.2% |
| 3-Year ReturnCumulative with dividends | +126.7% | +106.4% | +127.3% | +36.6% | -19.9% |
| 5-Year ReturnCumulative with dividends | +126.8% | +286.9% | +235.7% | +17.0% | -2.6% |
| 10-Year ReturnCumulative with dividends | +126.7% | +348.1% | +160.8% | +3.5% | +220.6% |
| CAGR (3Y)Annualised 3-year return | +31.4% | +27.3% | +31.5% | +11.0% | -7.1% |
Risk & Volatility
Evenly matched — MCK and CVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than GRDN's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.01x | -0.02x | 0.01x | 0.13x | 0.60x |
| 52-Week HighHighest price in past year | $41.36 | $999.00 | $233.60 | $88.63 | $395.52 |
| 52-Week LowLowest price in past year | $19.17 | $637.00 | $137.75 | $58.35 | $234.60 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +75.3% | +79.3% | +98.5% | +93.5% |
| RSI (14)Momentum oscillator 0–100 | 47.4 | 16.2 | 33.2 | 69.3 | 75.9 |
| Avg Volume (50D)Average daily shares traded | 461K | 757K | 1.7M | 7.4M | 7.9M |
Analyst Outlook
Evenly matched — CVS and UNH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: GRDN as "Buy", MCK as "Buy", CAH as "Buy", CVS as "Buy", UNH as "Buy". Consensus price targets imply 36.8% upside for CAH (target: $253) vs 4.2% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.06% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $38.00 | $994.86 | $253.38 | $96.75 | $385.43 |
| # AnalystsCovering analysts | 3 | 31 | 33 | 41 | 52 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% | +1.1% | +3.1% | +2.4% |
| Dividend StreakConsecutive years of raises | 0 | 17 | 20 | 0 | 25 |
| Dividend / ShareAnnual DPS | — | $2.69 | $2.04 | $2.67 | $8.70 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.3% | +3.4% | +1.8% | 0.0% | +1.7% |
GRDN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 1 (Valuation Metrics). 3 tied.
GRDN vs MCK vs CAH vs CVS vs UNH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GRDN or MCK or CAH or CVS or UNH a better buy right now?
For growth investors, Guardian Pharmacy Services, Inc.
(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 9x trailing P/E (20. 7x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GRDN or MCK or CAH or CVS or UNH?
On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 27.
9x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Guardian Pharmacy Services, Inc. 's 1. 53x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — GRDN or MCK or CAH or CVS or UNH?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -2. 6% for UnitedHealth Group Incorporated (UNH). Over 10 years, the gap is even starker: MCK returned +339. 0% versus CVS's +6. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GRDN or MCK or CAH or CVS or UNH?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.
02β versus Guardian Pharmacy Services, Inc. 's 1. 01β — meaning GRDN is approximately -6259% more volatile than MCK relative to the S&P 500. On balance sheet safety, Guardian Pharmacy Services, Inc. (GRDN) carries a lower debt/equity ratio of 17% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — GRDN or MCK or CAH or CVS or UNH?
By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.
(GRDN) is pulling ahead at 17. 9% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GRDN or MCK or CAH or CVS or UNH?
Guardian Pharmacy Services, Inc.
(GRDN) is the more profitable company, earning 3. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus 1. 0% for CAH. At the gross margin level — before operating expenses — GRDN leads at 19. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GRDN or MCK or CAH or CVS or UNH more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Guardian Pharmacy Services, Inc. 's 1. 53x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CVS Health Corporation (CVS) trades at 12. 4x forward P/E versus 28. 7x for Guardian Pharmacy Services, Inc. — 16. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 36. 8% to $253. 38.
08Which pays a better dividend — GRDN or MCK or CAH or CVS or UNH?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. GRDN does not pay a meaningful dividend and should not be held primarily for income.
09Is GRDN or MCK or CAH or CVS or UNH better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 1. 1% yield, +158. 8% 10Y return). Both have compounded well over 10 years (CAH: +158. 8%, GRDN: +125. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GRDN and MCK and CAH and CVS and UNH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GRDN is a small-cap high-growth stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; CVS is a mid-cap income-oriented stock; UNH is a large-cap quality compounder stock. CAH, CVS, UNH pay a dividend while GRDN, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.